Literature DB >> 3067116

Tianeptine and amitriptyline. Controlled double-blind trial in depressed alcoholic patients.

H Lôo1, R Malka, R Defrance, D Barrucand, J Y Benard, H Niox-Rivière, A Raab, A Sarda, G Vachonfrance, A Kamoun.   

Abstract

129 chronic alcoholic patients, withdrawn from alcohol and presenting major depression or dysthymic disorder, were treated for 4-8 weeks under double-blind conditions either with a new antidepressant, tianeptine (37.5 mg per day), or with amitriptyline (75 mg per day). Both groups presented steady improvement of the symptoms of depression during treatment, as scored on the Montgomery and Asberg Depression Rating Scale and the Hopkins Symptom Checklist self-evaluation; for the latter scale, the improvement was significantly greater in the tianeptine group. In addition to the improvement of mood, tianeptine also produced significant reduction of the somatic complaints of the depressed patients. Furthermore, tianeptine possesses anxiolytic activity, as shown by the change of the Hamilton Anxiety Rating Scale global score, similar to that produced by amitriptyline. The anxiolytic activity of tianeptine was not accompanied by any impairment of vigilance, unlike that of amitriptyline. Tianeptine produced rare, mild anticholinergic effects. The results obtained show that tianeptine is an effective anxiolytic antidepressant, with better safety than amitriptyline, suitable for use in the treatment of mood disorders following alcohol withdrawal.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3067116     DOI: 10.1159/000118439

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  10 in total

Review 1.  Tianeptine: a review of its use in depressive disorders.

Authors:  A J Wagstaff; D Ormrod; C M Spencer
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

2.  Kinetic profiles of tianeptine and its MC5 metabolite in plasma, blood and brain after single and chronic intraperitoneal administration in the rat.

Authors:  W Couet; J Girault; F Latrille; C Salvadori; J B Fourtillan
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Jan-Mar       Impact factor: 2.441

3.  Efficacy and safety of tianeptine in major depression: evidence from a 3-month controlled clinical trial versus paroxetine.

Authors:  Lionel Waintraub; Lucia Septien; Paul Azoulay
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

4.  Pharmacokinetic and pharmacodynamic interaction between the antidepressant tianeptine and oxazepam at steady-state.

Authors:  S Toon; B L Holt; S J Langley; F G Mullins; M Rowland; M S Halliday; C Salvadori; B Delalleau
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

5.  Tianeptine binding to human plasma proteins and plasma from patients with hepatic cirrhosis or renal failure.

Authors:  R Zini; D Morin; C Salvadori; J P Tillement
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

6.  Tianeptine and its main metabolite pharmacokinetics in chronic alcoholism and cirrhosis.

Authors:  R J Royer; M J Royer-Morrot; F Paille; D Barrucand; J Schmitt; R Defrance; C Salvadori
Journal:  Clin Pharmacokinet       Date:  1989-03       Impact factor: 6.447

7.  Development of a population pharmacokinetic database for tianeptine.

Authors:  T H Grasela; J B Fiedler-Kelly; C Salvadori; C Marey; R Jochemsen
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 8.  Neurobiological and clinical effects of the antidepressant tianeptine.

Authors:  Siegfried Kasper; Bruce S McEwen
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 9.  Tianeptine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression.

Authors:  M I Wilde; P Benfield
Journal:  Drugs       Date:  1995-03       Impact factor: 9.546

Review 10.  Antidepressants for the treatment of people with co-occurring depression and alcohol dependence.

Authors:  Roberta Agabio; Emanuela Trogu; Pier Paolo Pani
Journal:  Cochrane Database Syst Rev       Date:  2018-04-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.